


BDA RESEARCH LIMITED

BDA RESEARCH LIMITED
REPORT AND FINANCIAL STATEMENTS

31 December 2022

COMPANY NUMBER: 3339062



BDA RESEARCH LIMITED

DIRECTORS' REPORT

for the year ended 31 December 2022

The directors present their report and the audited financial statements of the company for the year ended 31 December 2022.

Principal activities

The company's principal activity is the carrying on of research into non-insulin dependant diabetes mellitus, primarily by way of the genetic mapping, molecular cloning and physiologic characterisation of genes.

Review of business

The company did not carry out any business activity in the year. All research agreements that the company had entered into came to an end during 2003 but the company may enter into other research agreements in the future.

The directors consider that the company's state of affairs is satisfactory.

Directors and their interests

The directors who held office during the year are given below

C Askew

At 31 December 2022, none of the directors held an interest in the issued share capital of the company.



By order of the board

C Askew

Director

Registered Office:
Wells Lawrence House
126 Back Church Lane
London
E1 1FH

Date: 4 August 2023

BDA RESEARCH LIMITED

STATEMENT OF DIRECTORS' RESPONSIBILITIES

We are required under company law to prepare financial statements for each financial period which give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period.

In preparing these financial statements we are required to:

- select suitable accounting policies and apply these consistently;
- make reasonable and prudent judgements and estimates;
- state whether applicable accounting standards have been followed and give details of any departures; and
- prepare the financial statements on a going concern basis unless in our view the company will be unable to continue in business.

We are also responsible for:

- keeping proper accounting records;
- safeguarding the company's assets; and
- taking reasonable steps for the prevention and detection of fraud.



By order of the board

C Askew

Director

Date: 4 August 2023

BDA RESEARCH LIMITED

PROFIT AND LOSS ACCOUNT

for the year ended 31 December 2022

	Notes	2022 £	2021 £
Turnover	1	-	-
Cost of sales		-	-
Gross profit		-	-
Administrative expenses		-	-
Operating profit	3	-	-
Interest receivable		-	-
Profit on ordinary activities before taxation		-	-
Taxation		-	-
Profit to be donated to Diabetes UK	10	-	-
Retained profit for the year after taxation		-	-
Retained profit brought forward		-	-
Retained profit carried forward		-	-

Continuing operations

None of the company's activities were acquired or discontinued during the year.

Total recognised gains and losses

The company's only recognised gains and losses for the period are those shown above.

BDA RESEARCH LIMITED

BALANCE SHEET

as at 31 December 2022

	Notes	2022 £	2021 £
Current assets			
Debtors	4	-	-
Cash at bank		<u>2</u>	<u>2</u>
		2	2
Creditors: amounts falling due within one year	5	<u>-</u>	<u>-</u>
Net assets		<u><u>2</u></u>	<u><u>2</u></u>
Capital and reserves			
Called up share capital	6	2	2
Profit and loss account		<u>-</u>	<u>-</u>
Equity shareholders' funds	7	<u><u>2</u></u>	<u><u>2</u></u>

The company was dormant throughout the year.

For the year ending 31 December 2022 the company was entitled to exemption from audit under section 480 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The director's acknowledge their responsibility for complying with the requirements of the Act with respect to accounting records and for the preparation of accounts.

The financial statements on pages 3 to 6 were approved by the Board of Directors on 4 August 2023.
and signed on its behalf by:



C Askew
Director

Date: 4 August 2023

BDA RESEARCH LIMITED

NOTES TO THE FINANCIAL STATEMENTS

31 December 2022

1 Accounting policies

(a) Basis of accounting

The financial statements have been prepared in accordance with applicable accounting standards and under the historical cost accounting rules.

(b) Turnover

Turnover represents research funding. Turnover is recognised as research is undertaken.

(c) Research expenditure

Research expenditure is expensed as incurred.

(d) Cash flow statement

The company has taken advantage of the exemption from preparing a cash flow statement conferred by Financial Reporting Standard No. 1 on the grounds that it is entitled to exemptions available in S.246-247 of the Companies Act 1985 for small companies.

2 Staff costs

The company had no employees during the year. None of the directors received any remuneration from the company for their services as directors.

3 Operating profit

2022

2021

£

£

The operating profit is stated after charging:

Exchange loss

-

-

4 Debtors: amounts falling due within one year:

Amounts recoverable on contracts

-

-

Due from ultimate parent undertaking

-

-

Tax recoverable

-

-

BDA RESEARCH LIMITED

NOTES TO THE FINANCIAL STATEMENTS

31 December 2022
(continued)

5	Creditors: amounts falling due within one year			2022	2021
				£	£
	Amount due to ultimate parent undertaking			-	-
	Donation due to ultimate parent undertaking			-	-
	Accruals and deferred income			-	-
				-	-
6	Called up share capital			2022	2021
		Number	£	Number	£
	Authorised:				
	Ordinary shares of £1 each	1,000	1,000	1,000	1,000
	Allotted, issued and fully paid:				
	Ordinary shares of £1 each	2	2	2	2
7	Equity shareholders' funds			2022	2021
				£	£
	At 1 January			2	2
	Profit for the year			-	-
	At 31 December			2	2
8	Ultimate parent undertaking				
	The company's parent undertaking is The British Diabetic Association operating as Diabetes UK, a charity registered in England and Wales (number 215199) and in Scotland (number SC039136) and a company limited by guarantee registered in England and Wales with number 00339181 and registered office at Wells Lawrence House, 126 Back Church Lane London E1 1FH.				
9	Related party transactions				
	The company has taken advantage of the exemption conferred by Financial Reporting Standard No. 8 paragraph 3(c), not to disclose transactions with Diabetes UK on the basis that consolidated group accounts are publicly available.				
10	Donation to Diabetes UK				
	The company's intention is to donate future profits to Diabetes UK.				